IFIH1 and clinically amyopathic dermatomyositis: Additionally, in the stratified analysis performed according to detection method, anti-MDA5 antibodies were significantly associated with CADM risk when: ELISAs were used to evaluate samples from 127 CADM patients and 134 healthy controls (OR = 41.24, 95% CI: 10.49–162.16, P < 0.001), in immunoprecipitation assays that compared 117 CADM patients and 112 healthy controls (OR = 49.05, 95% CI: 14.77–162.86, P < 0.001), and in immunoblot assays that compared 15 CADM patients and 25 healthy controls (OR = 57.80, 95% CI: 2.98–1122.24, P = 0.007).